Live
Endpoints NewsFDA guides pharma on explaining unapproved drugs to payorsClinical OMICsAI Model Predicts Radiation Uptake Before Treatment in Advanced Prostate CancerBioPharma DiveLegend surges on early data for ‘in vivo’ lymphoma cell therapyWatersTranscript : Waters Corporation Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 10 - marketscreener.comEndpoints NewsWhat it will take for more employer GLP-1 coverageBioPharma DiveHouse bill aims to crack down on China biotech dealsBioPharma DiveNewLimit’s $435M megaround; Lilly’s busy dealmaking weekLonza NewsLonza Enhances Biologics Preclinical Development Offering - Contract PharmaLabiotechHighlights of ASCO 2026: how is cancer care evolving?Clinical OMICsExperienced Physicians Still Beat AI at Skin Cancer DiagnosisEndpoints NewsRegeneron doubles down on CytomX after other pharmas walked awayClinical OMICsArthur Caplan: The Right to Life, Liberty, and Pursuit of Health
Agilent Mar 3, 2026

Agilent (NYSE: A) CEO surrenders 279 shares to cover RSU tax liability - Stock Titan

Agilent (NYSE: A) CEO surrenders 279 shares to cover RSU tax liability - Stock Titan

Original
Body unavailable. Use the original source.